Drug Approval | December 04, 2025
FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Here's a development that aims to keep your blood pressure in check. Literally!
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Subscribe To Our Newsletter & Stay Updated
